As a result, we now know of more than 10 genes mutated in >5% of cases of AML–NK and of several others mutated less often.4, 5, 6 Additionally, it has become clear that mutations other than those affecting FLT3,7NPM18 and CEBPA9 have a significant impact on prognosis and can help stratify anti-AML therapy for individual patients.4 In this light, many are calling for a shift towards a classification system for AML–NK based primarily on mutational profiling.4 Here, FLT3 is linked to acute myeloid leukemia.